Business Wire

LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry ™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic ...
Business Wire

LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry™ ...
Monthly Prescribing Reference

Adbry Autoinjector Approved for Moderate to Severe Atopic Dermatitis

The new single-dose autoinjector is available in a 300mg/2mL dosage strength and is intended for use in adults only. The Food and Drug Administration (FDA) has approved a new single-dose autoinjector ...
Monthly Prescribing Reference

Adbry Approved for Moderate to Severe Atopic Dermatitis

The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD. The Food and Drug Administration ...